Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A study to determine effects of esketamine on emotion processing and cognitive functioning, both acutely and sub-chronically

Next Previous
Trial Profile

A study to determine effects of esketamine on emotion processing and cognitive functioning, both acutely and sub-chronically

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 04 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Esketamine (Primary)
  • Indications Bipolar depression; Depression; Depressive disorders
  • Focus Therapeutic Use

Most Recent Events

  • 04 Feb 2025 New trial record
  • 01 Jan 2025 Results published in the World Journal of Biological Psychiatry
  • 01 Jan 2025 According to Results published in the Media Release, study was supported by the DYNAMIC centre, funded by the LOEWE program of the Hessian Ministry of Science and Art.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top